Frontiers in Oncology (Apr 2022)

Impact of Adjuvant Chemotherapy on Variant Histology of Upper Tract Urothelial Carcinoma: A Propensity Score-Matched Cohort Analysis

  • Chi-Wen Lo,
  • Chi-Wen Lo,
  • Wei-Ming Li,
  • Wei-Ming Li,
  • Wei-Ming Li,
  • Wei-Ming Li,
  • Wei-Ming Li,
  • Hung-Lung Ke,
  • Hung-Lung Ke,
  • Hung-Lung Ke,
  • Hung-Lung Ke,
  • Hung-Lung Ke,
  • Yi-Huei Chang,
  • Yi-Huei Chang,
  • Yi-Huei Chang,
  • Hsi-Chin Wu,
  • Hsi-Chin Wu,
  • Hsi-Chin Wu,
  • I-Hsuan Alan Chen,
  • Jen-Tai Lin,
  • Chao-Yuan Huang,
  • Chung-Hsin Chen,
  • Jen-Shu Tseng,
  • Jen-Shu Tseng,
  • Jen-Shu Tseng,
  • Wun-Rong Lin,
  • Wun-Rong Lin,
  • Wun-Rong Lin,
  • Yuan-Hong Jiang,
  • Yu-Khun Lee,
  • Chung-You Tsai,
  • Chung-You Tsai,
  • Shiu-Dong Chung,
  • Shiu-Dong Chung,
  • Shiu-Dong Chung,
  • Thomas Y. Hsueh,
  • Thomas Y. Hsueh,
  • Thomas Y. Hsueh,
  • Allen W. Chiu,
  • Allen W. Chiu,
  • Allen W. Chiu,
  • Yeong-Chin Jou,
  • Yeong-Chin Jou,
  • Ian-Seng Cheong,
  • Ian-Seng Cheong,
  • Yung-Tai Chen,
  • Jih-Sheng Chen,
  • Bing-Juin Chiang,
  • Bing-Juin Chiang,
  • Bing-Juin Chiang,
  • Chih-Chin Yu,
  • Chih-Chin Yu,
  • Wei Yu Lin,
  • Wei Yu Lin,
  • Wei Yu Lin,
  • Chia-Chang Wu,
  • Chia-Chang Wu,
  • Chuan-Shu Chen,
  • Chuan-Shu Chen,
  • Chuan-Shu Chen,
  • Han-Yu Weng,
  • Yao-Chou Tsai,
  • Yao-Chou Tsai

DOI
https://doi.org/10.3389/fonc.2022.843715
Journal volume & issue
Vol. 12

Abstract

Read online

BackgroundThe advantage of adjuvant chemotherapy for upper urinary tract urothelial cancer (UTUC) has been reported, whereas its impact on upper tract cancer with variant histology remains unclear. We aimed to answer the abovementioned question with our real-world data.Design, Setting, and ParticipantsPatients who underwent radical nephroureterectomy (RNU) and were confirmed to have variant UTUC were retrospectively evaluated for eligibility of analysis. In the Taiwan UTUC Collaboration database, we identified 245 patients with variant UTUC among 3,109 patients with UTUC who underwent RNU after excluding patients with missing clinicopathological information.InterventionThose patients with variant UTUC were grouped based on their history of receiving adjuvant chemotherapy or not.Outcome Measurements and Statistical AnalysisPropensity score matching was used to reduce the treatment assignment bias. Multivariable Cox regression model was used for the analysis of overall, cancer-specific, and disease-free survival.Results and LimitationsFor the patients with variant UTUC who underwent adjuvant chemotherapy compared with those without chemotherapy, survival benefit was identified in overall survival in univariate analysis (hazard ratio (HR), 0.527; 95% confidence interval (CI), 0.285–0.973; p = 0.041). In addition, in multivariate analysis, patients with adjuvant chemotherapy demonstrated significant survival benefits in cancer-specific survival (OS; HR, 0.454; CI, 0.208–0.988; p = 0.047), and disease-free survival (DFS; HR, 0.324; 95% CI, 0.155–0.677; (p = 0.003). The main limitations of the current study were its retrospective design and limited case number.ConclusionsAdjuvant chemotherapy following RNU significantly improved cancer-related survivals in patients with UTUC with variant histology.

Keywords